generated the first bispecific aptamers consisting of a bivalent 4–1BB aptamer and a tumor–specific PSMA aptamer, enhancing the conjugate delivery to the tumor niche and activation of costimulatory responses. This evidence concerns the gene FOLH1 and neoplasm.